<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72009">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02168309</url>
  </required_header>
  <id_info>
    <org_study_id>Pro34034</org_study_id>
    <nct_id>NCT02168309</nct_id>
  </id_info>
  <brief_title>Oral Nifedipine Versus Oral Labetalol</brief_title>
  <official_title>Comparison of Oral Nifedipine to Oral Labetolol for the Management of Severe Postpartum Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study's aim is to determine whether oral extended release nifedipine is superior to
      oral labetolol for the management of postpartum severe hypertension, specifically time to
      achieve goal blood pressure, and shortening hospital stay. Our hypothesis is that oral
      extended release nifedipine is superior to oral labetolol for achieving goal blood pressure
      in the postpartum period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time (hours) to attain sustained blood pressure goal after treatment initiated with antihypertensive medication</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total length of hospital stay in hours</measure>
    <time_frame>48-96Hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Severe Postpartum Hypertension</condition>
  <arm_group>
    <arm_group_label>Labetalol</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Labetalol 200mg PO BID starting dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nifedipine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Nifedpine XL starting at dose 30mg PO daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Labetalol</intervention_name>
    <description>Titrate up for blood pressure control</description>
    <arm_group_label>Labetalol</arm_group_label>
    <other_name>Oral labetalol starting at dose 200mg PO BID</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine</intervention_name>
    <description>Titrate up to achieve blood pressure control</description>
    <arm_group_label>Nifedipine</arm_group_label>
    <other_name>Oral nifedipine 30mg XL PO starting</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years with the abililty to give informed consent

          -  Intrauterine pregnancy ≥ 32 weeks

          -  Postpartum

          -  Persistent postpartum blood pressures ≥ 160/105 on two or more occasions

          -  Primary obstetrician amenable to starting either study medication in the postpartum
             period

        Exclusion Criteria:

          -  Use of other oral antihypertensives concomitantly

          -  Known AV heart block

          -  HR &lt;60 or &gt;120

          -  Absolute contraindication to nifedipine or labetolol such as allergy

          -  Significant renal disease (Cr &gt;1.5 mg/dL)

          -  Heart failure

          -  Moderate persistent or severe asthma

          -  Preexisting diagnosis of chronic hypertension with medical treatment before delivery

          -  Chronic hypertension
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 31, 2017</lastchanged_date>
  <firstreceived_date>June 17, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Sarah Kilpatrick</investigator_full_name>
    <investigator_title>Chair, Department of Obstetrics &amp; Gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nifedipine</mesh_term>
    <mesh_term>Labetalol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
